Lysophosphatidylglycerol in Asthma Pathogenesis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06327516

Enrollment

250

Registered

2024-03-25

Start date

2015-01-01

Completion date

2025-06-30

Last updated

2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

asthma, lysophosphatidylglycerol, Treg

Brief summary

The study aims to investigate the relationship between the small molecule metabolite lysophosphatidylglycerol and asthma clinical features and explore its involvement in asthma pathogenesis.

Detailed description

This study screened LPG as a asthma marker by performing metabolomics of the included asthma patients and normal controls, explored the relationship between LPG and clinical features of asthma (including acute exacerbation, asthma control state, asthma treatment steps，lung function, and inflammatory signals including eosinophils, FeNO and total IgE), and further performed in vitro tests to investigate the specific mechanism of LPG's involvement in asthma inflammation through its influence on Treg function.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

1\. clinical diagnosis of asthma.

Exclusion criteria

1. Combined with chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypopnea syndrome, malignant tumor 2. Combined with acute and chronic respiratory failure 3. Combined with severe cardiovascular disease 4. Pregnant woman.

Design outcomes

Primary

Measure	Time frame	Description
lipidomics	when enrolled	collect blood for lipidomic analysis and in vitro assays on Day1

Countries

China

Contacts

Primary ContactChun Chang

doudou1977bysy@sina.com15810075362

Outcome results